Recombinant Proteins Market

Recombinant proteins are the new combination of genes which can be used in the formation of DNA. Recombinant DNA technology assists in the production of wild type and modified human, mammalian proteins in mass quantities. The proteins are made from cloned DNA sequences which usually encode an enzyme or protein with the known function. They are made through genetic engineering, which is also known as gene splicing or recombinant DNA technology. The recombinants can be gain by putting human, animal, or plant genes into the genetic material of mammalian, bacteria, or yeast cells. Government initiate for the prevention of bacterial diseases and increasing elderly diseases population and this resultant in a rise in infected disease prevalence, the requirement for affordable treatment options and digitalization of healthcare systems are factors which will accelerate the global recombinant protein market during the forecast period. Recombinant protein is technologically advance and is designed specifically to enhance health outcomes at any point. Additionally, in the real world, practical applications of these technologies can enhance the individual’s health and boost better outcomes of the population as a whole. The technological advancement in population health expands beyond big data applications for quality assessment and benchmarking capabilities. Also, technology allows the rapid aggregation of individual patient’s data to identify key patterns in large populations. Advancement in technology which supports recombinant protein such as to maintain patient dashboard, remote patient monitoring clinical grade, data aggregation, automated care management outreach, telemedicine, clinical intelligence/analytics, patient engagement, risk stratification. Thus, the effect of this factor on the recombinant protein market is projected to increase soon with constantly evolving technologies. On the other hand, dearth of data management expertise and skilled analysts, hesitancy to move from conventional systems and safety concerns pertaining to patient information are few of the major constraints on recombinant protein market growth.

Furthermore, the Asia Pacific region is anticipated to provide potential growth opportunities to market players in the coming years, owing to the diversified healthcare markets in this region, the rising incidence of infectious and chronic disorders, and increasing R&D initiatives to develop innovative proteomic and genomic techniques. In addition, the growth of the aging population, rising income levels, developments in healthcare infrastructure, rising healthcare expenditure, and the low-cost manufacturing benefit provided by emerging APAC countries are likely to prompt market players to invest in the region. Regulatory policies in Asia are also more flexible and business-friendly, which caters to attract the attention of large corporations already facing growing competition in mature markets.

The global Recombinant Proteins Market is segregated on the basis of Type of Product as Antibodies, Hormones, Growth Factors, Cytokines and Others. Based on Application the global Recombinant Proteins Market is segmented in Therapeutic Use, Research Application and Biotechnology Industry. Based on End User the global Recombinant Proteins Market is segmented in Biotechnology Companies, Research Institutes and Others.

The global Recombinant Proteins Market report provides geographic analysis covering regions, such as Europe, North America, Asia Pacific, and Rest of The World. The Recombinant Proteins Market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Competitive Analysis

Thermo Fisher Scientific, Inc., Miltenyi Biotech, Sino Biological Inc., Merck KGaA, Abcam plc and others are among the major players in the global Recombinant Proteins Market. The companies studied in terms of product strategy and various n several growth and expansion strategies to gain a competitive edge in the market. The major players not only follow value chain integration with business operations in multiple stages of the value chain.

• In April 2017, McKesson Corporation declared the completion of the acquisition of CoverMyMeds LLC-a developer of Electronic Prior Authorization (ePA) solutions. It also automates the process of prior endorsement for more than 500 EHR systems, 49,000 pharmacies, 700,000 suppliers, most of the health plans and Pharmacy Benefit Managers (PBMs).
• In December 2017, Royal Philips acquired VitalHealth, in order to expand its presence in the field of population health, providing Biopharmaceutical Production recombinant protein solutions.
• In 2020, Merck KGaA (Germany) partnered with Donghao Lansheng (Group) Co., Ltd. (China). This partnership aims to navigate a new import policy in China. It will enable Merck for the customs clearance of research materials for biomedical innovation and analytical use.

The global Recombinant Proteins Market has been segmented as below:

Recombinant Proteins Market, By Type of Product

• Antibodies
• Hormones
• Growth Factors
• Cytokines
• Others

Recombinant Proteins Market, By Application

• Therapeutic Use
• Research Application
• Biotechnology Industry

Recombinant Proteins Market, By End User

• Biotechnology Companies
• Research Institutes
• Others

Recombinant Proteins Market, By Region

• Europe
• North America
• Asia Pacific
• Rest of The World

Recombinant Proteins Market, By Company

• Thermo Fisher Scientific, Inc.
• Miltenyi Biotech
• Sino Biological Inc.
• Merck KGaA
• Abcam plc
• Biolegend
• Bio-Rad Laboratories, Inc.
• GenScript Biotech Corporation
• Enzo Life Sciences, Inc.
• BPS Bioscience, Inc.
• PeproTech, Inc.
• Proteintech Group, Inc.
• Abnova Corporation
• R&D Systems
• STEMCELL Technologies Inc
• RayBiotech Inc
• CellGenix GmbH
• ACROBiosystems
• ProSpec-TechnoGene Ltd.
• Neuromics
• RICHCORE LIFESCIENCES PVT LTD
• Icosagen AS
• ProteoGenix
• United States Biological

The report covers the below scope:

• Global Recombinant Proteins Market sizes from 2020 to 2026, along with CAGR for 2020-2026
• Market size comparison for 2019 vs 2026, with actual data for 2019, estimates for 2019 and forecast from 2020 to 2026
• Global Recombinant Proteins Market trends, covering comprehensive range of consumer trends & manufacturer trends
• Value chain analysis covering participants from raw material suppliers to the downstream buyer in the global Recombinant Proteins Market
• Major market opportunities and challenges in forecast timeframe to be focused
• Competitive landscape with analysis on competition pattern, portfolio comparisons, development trends and strategic management
• Comprehensive company profiles of the key industry players

The years considered for the study are as follows:

• Base year - 2019
• Estimated year - 2019
• Projected year - 2020
• Forecast period - 2021 to 2026

Report Scope:

The global Recombinant Proteins Market report scope includes detailed study covering underlying factors influencing the industry trends. The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies. The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Recombinant Proteins Market share. Major industry players with significant revenue share include Thermo Fisher Scientific, Inc., Miltenyi Biotech, Sino Biological Inc., Merck KGaA, Abcam plc and others.

Why to Buy this Report:

• Gain detailed insights on the Recombinant Proteins industry trends
• Find complete analysis on the market status
• Identify the Recombinant Proteins Market opportunities and growth segments
• Analyse competitive dynamics by evaluating business segments & product portfolios
• Facilitate strategy planning and industry dynamics to enhance decision making

Target Audience:

• The report targeted towards the existing players in the industry is as follows:
• Market Manufacturers/Service Providers
• Market Wholesale/Traders
• Investment and Financial Institutions

Free and Paid Customization based on the requirement

1.      Introduction

1.1.       Key Points

1.2.      Report Description

1.3.      Markets Covered

1.4.      Stakeholders

2.     Research Methodology

2.1.      Research Scope

2.2.     Research Methodology

2.2.1.     Market Research Process

2.2.2.    Research Methodology

2.2.2.1.           Secondary Research

2.2.2.2.          Primary Research

2.2.2.3.          Models for Estimation

2.3.     Market Size Estimation

2.3.1.     Bottom-Up Approach

2.3.2.    Top-Down Approach

3.     Executive Summary

4.    Market Overview

4.1.      Introduction

4.2.     Drivers

4.3.     Restraints

4.4.     Opportunities

4.5.     Challenges

5.     Recombinant Proteins Market, By Type of Product

5.1.      Key Points

5.2.  Antibodies

5.3.  Hormones

5.4.  Growth Factors

5.5.  Cytokines

5.6.  Others

6.    Recombinant Proteins Market, By Application

6.1.      Key Points

6.2. Therapeutic Use

6.3. Research Application

6.4. Biotechnology Industry

7.     Recombinant Proteins Market, By End User

7.1.      Key Points

7.2.  Biotechnology Companies

7.3.  Research Institutes

7.4.  Others

8.    Competitive Landscape

8.1.      Introduction

8.2.     Start-up companies- Recombinant Proteins Market

8.3.     Recent Developments

8.3.1.     Mergers & Acquisitions

8.3.2.    New Product Developments

8.3.3.    Portfolio/Production Capacity Expansions

8.3.4.    Joint Ventures, Collaborations, Partnerships & Agreements

8.3.5.    Others

9.    Company Profile

9.1.  Thermo Fisher Scientific, Inc.

9.2. Miltenyi Biotech

9.3. Sino Biological Inc.

9.4. Merck KGaA

9.5.  Abcam plc

9.6. Biolegend

9.7.  Bio-Rad Laboratories, Inc.

9.8. GenScript Biotech Corporation

9.9. Enzo Life Sciences, Inc.

9.10.    BPS Bioscience, Inc.

9.11.      PeproTech, Inc.

9.12.    Proteintech Group, Inc.

9.13.     Abnova Corporation

9.14.    R&D Systems

9.15.     STEMCELL Technologies Inc

9.16.    RayBiotech Inc

9.17.     CellGenix GmbH

9.18.    ACROBiosystems

9.19.    ProSpec-TechnoGene Ltd.

9.20.   Neuromics

9.21.    RICHCORE LIFESCIENCES PVT LTD

9.22.   Icosagen AS

9.23.    ProteoGenix

9.24.   United States Biological